Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced full results...
HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. – a leading drug development organization Harpoon Therapeutics, Inc. (NASDAQ: HARP), a...
Enrollment Sufficient to Support the Interim Efficacy Analysis Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical...
-Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized...
A First-in-Class Ophthalmological Recombinant Fully Human Bi-specific Fusion Protein Targeting VEGF and Complement Proteins Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality...
Clinical trials take a group of individuals and evaluate how certain treatment effects them. Data is collected and analyzed to then determine educated findings and results. It’s crucial to keep patients involved during clinical trials, as otherwise, it can cause...
Email
Text